Settlements between originators and generics can benefit consumers, claims research
A recent study claims that US consumers and the federal government have saved around $25.5 billion on the cost of drugs since 2005 due to patent dispute settlements between pharmaceutical originators and generic manufacturers. While ‘pay-for-delay’…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.